Chimeric antibodies for the treatment of hematologic malignancy

T-Cell Receptor and Immunoglobulin Gene Rearrangements in Acute Myeloid and Undifferentiated Leukemias of Adults: Correlation with Weak Surface Expression of CD45 and CDw52 Antigens.

Leukemia & lymphoma·2016

Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies.

Leukemia & lymphoma·2016

Laser-induced fluorescence measurement of oxygen atoms above a catalytic combustor surface.

Applied optics·2010

Time-resolved CH (A(2)Delta and B(2)Sigma(-)) laser-induced fluorescence in low pressure hydrocarbon flames.

Applied optics·2010

Activity of thalidomide and lenalidomide in mantle cell lymphoma.

Acta haematologica·2009

Laser linewidth narrowing induced by amplifier gain saturation.

Optics letters·2009

Clinical Trials and Translational Advances in Metabolic Targeting.

Cancer treatment and research·2026

Tools and Technologies for Studying Cancer Metabolism.

Cancer treatment and research·2026

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Cancer treatment and research·2026

Biomarkers of Cancer Metabolism and Therapeutic Response.

Cancer treatment and research·2026

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Cancer treatment and research·2026

Metabolic Reprogramming in Cancer Stem Cells.

Cancer treatment and research·2026

Increased anergic B cells and decreased antibody-secreting cells during romiplostim treatment in patients with immune thrombocytopenia.

British journal of haematology·2026

Passive Transfer of Hepatitis B Core Antibody Following Intravenous Ig Administration: Clinical Implications and Considerations.

ACR open rheumatology·2026

Investigating the role of serum IL-6 in predicting outcomes of b-cell depleting therapy in multiple sclerosis: a retrospective cohort study.

BMC neurology·2026

iPSC-derived neurospheres: A cellular platform for Tau and Alzheimer's disease immunotherapy.

Advances in immunology·2026

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Lancet (London, England)·2026

Expanding the therapeutic landscape of Still's disease: the emerging role of JAK inhibitors.

Expert opinion on pharmacotherapy·2026

Related Experiment Videos

Chimeric antibodies for the treatment of hematologic malignancy

Related Concept Videos

T-Cell Receptor and Immunoglobulin Gene Rearrangements in Acute Myeloid and Undifferentiated Leukemias of Adults: Correlation with Weak Surface Expression of CD45 and CDw52 Antigens.

Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies.

Laser-induced fluorescence measurement of oxygen atoms above a catalytic combustor surface.

Time-resolved CH (A(2)Delta and B(2)Sigma(-)) laser-induced fluorescence in low pressure hydrocarbon flames.

Activity of thalidomide and lenalidomide in mantle cell lymphoma.

Laser linewidth narrowing induced by amplifier gain saturation.

Clinical Trials and Translational Advances in Metabolic Targeting.

Tools and Technologies for Studying Cancer Metabolism.

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Biomarkers of Cancer Metabolism and Therapeutic Response.

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Metabolic Reprogramming in Cancer Stem Cells.

Increased anergic B cells and decreased antibody-secreting cells during romiplostim treatment in patients with immune thrombocytopenia.

Passive Transfer of Hepatitis B Core Antibody Following Intravenous Ig Administration: Clinical Implications and Considerations.

Investigating the role of serum IL-6 in predicting outcomes of b-cell depleting therapy in multiple sclerosis: a retrospective cohort study.

iPSC-derived neurospheres: A cellular platform for Tau and Alzheimer's disease immunotherapy.

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Expanding the therapeutic landscape of Still's disease: the emerging role of JAK inhibitors.

Related Experiment Videos

Chimeric antibodies for the treatment of hematologic malignancy

Related Concept Videos

Related Articles